arrow
K

Kentaro Nagaoka

University of Toyama
H指数:12
被引数:488

个人简介

暂无内容

教育背景

暂无内容

工作经历

暂无内容

荣誉奖项

暂无内容

Association between tazobactam-piperacillin exposure and the subsequent emergence in gram-negative rods: Findings from a single-institution cohort study

替卡西林-他唑巴坦暴露与随后革兰氏阴性杆菌出现之间的关系:一项单机构队列研究的结果

2026-08-010
PRE
A novel melting temperature mapping method may improve the prediction of postoperative intra-abdominal infection after pancreatoduodenectomy

一种新型熔融温度映射方法可能改善胰十二指肠切除术后腹腔内感染的预测

2025-10-010
PRE
High feasibility of salivary therapeutic drug monitoring in linezolid, but lower feasibility in tedizolid: a single-dose study in healthy subjects and a monocentric prospective exploratory study in patients who received linezolid

唾液治疗药物监测在利奈唑胺中具有高度可行性,但在 tedizolid 中可行性较低:一项在健康受试者中进行的单剂量研究以及一项在接收利奈唑胺治疗的患者中进行的单中心前瞻性探索性研究。

2025-07-010
PRE
Effects of extended anaerobic antibiotic coverage on anaerobic bloodstream infection: A multisite retrospective study

延长厌氧菌抗生素覆盖对厌氧菌血流感染的影响:一项多中心回顾性研究

2025-02-010
OAAI
Clinical phenotype of anaerobic bacteremia unaccompanied by detectable abscess lesion: a 10-year retrospective, multicenter, observational-cohort study

厌氧性菌血症不伴有可检测的脓肿病变的临床表型: 一项为期10年的回顾性、多中心、观察性队列研究

2024-05-201
PRE
Mortality risk factors and fulminant sub-phenotype in anaerobic bacteremia: a 10-year retrospective, multicenter, observational cohort study

厌氧菌血症的死亡率危险因素和暴发性亚表型: 一项为期10年的回顾性,多中心,观察性队列研究

2024-01-033
PRE
Neutralizing Antibody Response of the Wild-Type/Omicron BA.1 Bivalent Vaccine as the Second Booster Dose against Omicron BA.2 and BA.5

野生型/Omicron BA.1二价疫苗的中和抗体反应作为针对Omicron BA.2和BA.5的第二次加强剂量

2023-04-138
OAAI